DU
Therapeutic Areas
Dermapharm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Yusimry™ (adalimumab biosimilar) | Chronic Inflammatory Diseases (e.g., Rheumatoid Arthritis, Psoriasis, Crohn's Disease) | Approved |
| Etanercept Biosimilar | Chronic Inflammatory Diseases (e.g., Rheumatoid Arthritis, Psoriasis) | Approved |
| Various Generic/Branded Generic Projects | Dermatology, Pain, Cardiovascular, Anti-infectives | Development/Registration |
Leadership Team at Dermapharm
DH
Dr. Hans-Georg Feldmeier
Chairman of the Management Board (CEO)
DJ
Dr. Jürgen Groß
Member of the Management Board (CFO)
DB
Dr. Bernd Wegener
Member of the Management Board (COO)
DS
Dr. Stefan Wohlfeil
Member of the Management Board (CSO)
DM
Dr. Michael Schlenk
Member of the Management Board (CMO)
DR
Dr. Rolf H. Schöttle
Deputy Chairman of the Supervisory Board
DJ
Dr. Jutta Braun
Member of the Supervisory Board
TK
Thomas Kessel
Member of the Supervisory Board
DJ
Dr. Jochen Maas
Member of the Supervisory Board
DG
Dr. Gerd Weghorn
Member of the Supervisory Board